Johnson & Johnson quarterly profit rises 4.5%

FAN Editor

Oct 16 (Reuters) – Johnson & Johnson on Tuesday reported quarterly profit above estimates and raised its full-year forecast, as demand for its cancer drugs Zytiga and Imbruvica helped offset decline in sales of blockbuster drug, Remicade.

Continue Reading Below

J&J said it now expects adjusted 2018 earnings per share to be in the range of $8.13 and $8.18, up from its previous range of $8.07 to $8.17.

Sales of rheumatoid arthritis treatment Remicade fell 16.3 percent to $1.38 billion in the quarter as pressure from biosimilars intensified. Analysts had expected revenue of $1.36 billion, according to Barclays.

As Remicade faces increased competition and the company’s consumer and medical health businesses come under pressure, J&J has been inking deals and spending more on its drug pipeline to beef up sales.

The health care conglomerate’s net earnings rose to $3.93 billion, or $1.44 per share, in the third quarter, from $3.76 billion, or $1.37 per share, a year earlier.

Excluding items, the company earned $2.05 per share. Analysts on average expected $2.03 per share, according to I/B/E/S data from Refinitiv.

Sales rose 3.6 percent to $20.35 billion, above analysts’ average estimate of $20.05 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber and Arun Koyyur)

Free America Network Articles

Leave a Reply

Next Post

"You should die in a locked closet," judge tells man guilty of killing girl

DALLAS  – The Texas man accused of savagely beating his girlfriend’s daughter to death in 2016 has been found guilty of capital murder. CBS Dallas Fort Worth reports that Charles Wayne Phifer was sentenced to life in prison without parole for killing 4-year-old Leiliana Wright. “I don’t think life in […]